-
Treat-to-target or treat-to-dissolve strategy to improve gout treatment Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-26 Pascal Richette, Nicola Dalbeth
Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
-
Thyroid hormone induces ossification and terminal maturation in a preserved OA cartilage biomimetic model Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 N. M. Korthagen, E. Houtman, I. Boone, R. Coutinho de Almeida, K. Sivasubramaniyan, R. Mahdad, R. G. H. H Nelissen, Y. F. M. Ramos, M. A Tessari, I. Meulenbelt
To characterize aspects of triiodothyronine (T3) induced chondrocyte terminal maturation within the molecular osteoarthritis pathophysiology using the previously established T3 human ex vivo osteochondral explant model. RNA-sequencing was performed on explant cartilage obtained from OA patients (n = 8), that was cultured ex vivo with or without T3 (10 ng/ml), and main findings were validated using
-
Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-25 Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha
We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes
-
-
-
-
-
E050 Angiotensin converting enzyme for the diagnosis of childhood sarcoidosis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Madeleine C Mackay, Samundeeswari Deepak, Kishore Warrier, Satyapal Rangaraj
Background/Aims Childhood sarcoidosis is a rare multisystem inflammatory granulomatous disease. The prevalence of sarcoidosis in children is unknown due to its rarity. A review of sarcoidosis in Denmark found an incidence in children < 15 years of 0.22-0.27 per 100 000/year. Diagnosis can be challenging given the varied presentations due to multisystem involvement. There is no one laboratory test that
-
P187 Fatigue in people with polymyalgia rheumatica: a key unmet need? Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sara Muller, John Belcher, Samantha Hider, Toby Helliwell, Christian D Mallen
Background/Aims Polymyalgia rheumatica (PMR) is common in older adults, causing severe pain and stiffness, particularly in the shoulder and hip girdles. Glucocorticoids treatment generally focusses on reducing pain and stiffness, but there are other aspects to quality of life. Fatigue is a well-recognised symptom in other inflammatory rheumatological conditions and has been highlighted by people with
-
OA04 Efficacy and safety of nipocalimab in patients with moderate to severe active rheumatoid arthritis: the multicenter, randomised, double-blinded, placebo-controlled phase 2a IRIS-RA study Rheumatology (IF 5.5) Pub Date : 2024-04-24 Peter C Taylor, George Schett, Fowzia Ibrahim, Bei Zhou, Jocelyn Leu, Sophia Liva, Quingmin Wang, Ricardo Rojo Cella, Chetan S Karyekar, Kaiyin Fei
Background/Aims Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with autoantibodies. Despite the use of targeted therapies, up to half of patients fail to achieve remission or low disease activity (LDA). Anti-citrullinated protein antibodies (ACPAs), key autoantibodies that predict progression of joint destruction in RA, are largely an immunoglobulin G (IgG) isotype. Nipocalimab
-
E041 Feasibility and acceptability of electronic patient reported outcome measures in the routine care of people with inflammatory arthritis: Haywood Arthritis Portal study Rheumatology (IF 5.5) Pub Date : 2024-04-24 Natasha Cox, Chelsea Kettle, Haboo Wang, Shouma Dutta, Jon Packham, James Galloway, Jonathan Hill, Sara Muller, Samantha Hider, Zoe Paskins, Laurna Bullock, Ian C Scott
Background/Aims Electronic patient-reported outcome measures (ePROMs) assessing disease activity, function, pain, and quality of life can facilitate innovative inflammatory arthritis (IA) care, such as automating patient-initiated follow-up. This mixed-methods study evaluated whether their use is feasible and acceptable in routine care of people with inflammatory arthritis in an NHS setting. Methods
-
P160 High levels of CD19 expression is a characteristic feature of age-associated B cells in ageing and autoimmunity Rheumatology (IF 5.5) Pub Date : 2024-04-24 Kavina Shah, Vanessa Poon, Samuel J Taylor, Christian Klein, Florian Kollert, Franz Schuler, Sanjana Mathur, Madhura Castelino, Debajit Sen, Jo Cambridge, Mark Cragg, Maria Leandro, Arne Akbar, Venkat Reddy
Background/Aims Recent evidence implicates an important role for age-associated B cells (ABCs), defined as CD19+IgD-CD27-T-bet+ B cells, in healthy ageing, following viral infection and in active SLE. We know that co-receptors of the B cell receptor (BCR) such as CD19 and other activating receptors can influence B cell activation through distinct pathways. Therefore, we compared the expression of CD19
-
P001 An audit to assess whether patients who had a delayed or missed denosumab dose during the covid-19 pandemic came to any harm or suffered a subsequent fracture Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sumaiya Rehman, Shabina Sultan
Background/Aims Denosumab is licensed by NICE for the secondary prevention of osteoporosis in patients who are unable to comply, have an intolerance, or contraindication to bisphosphonates. With the outbreak of Covid-19, denosumab appointments were delayed. A delay of denosumab doses by more than 16 weeks is associated with an increased risk of vertebral fractures. This audit was carried out to see
-
P153 Exploring the relationships between objective and subjective clinical measures in Sjogren's Syndrome Rheumatology (IF 5.5) Pub Date : 2024-04-24 Joe S Berry, Jessica Tarn, Dennis Lendrem, John Casement, Wan-Fai Ng
Background/Aims Patient Reported Outcome Measures (PROMs) are standardised, validated questionnaires designed to measure the patient’s perception of their disease. Discordance between the patient’s perspective and objective clinical measures (clinical scores, laboratory data) has led to increased interest in PROMs in Sjogren’s syndrome (SS). Initial concern about the subjectivity of PROMs has given
-
P036 Missing vital steps: why does my rheumatology team never speak to me about exercise? Rheumatology (IF 5.5) Pub Date : 2024-04-24 Ailsa M Bosworth, William J Gregory
Background/Aims UK Rheumatology services are stretched. Rollout of Patient Initiated Follow Up and pressure on job plans/clinic templates mean people with inflammatory arthritis (IA) may spend less time with their rheumatology team. An important but insufficient aspect of care in people with IA is empowering them to acquire good understanding of their disease and building their ability to deal effectively
-
P115 Thousands of rheumatoid arthritis & juvenile idiopathic arthritis patients benefit from interactive National Rheumatoid Arthritis Society broadcasts Rheumatology (IF 5.5) Pub Date : 2024-04-24 Clare B Jacklin
Background/Aims Pressures on NHS services results in many rheumatology patients missing out on vital information that can support them in understanding and managing their conditions. During the COVID pandemic, NRAS took to social media to host regular live interactive broadcasts to keep people informed on the latest regarding vaccines, staying safe and treatments etc. These proved such a successful
-
OA41 Exploring patterns of patient engagement with electronic patient reported outcome measures in inflammatory arthritis using latent class growth modelling Rheumatology (IF 5.5) Pub Date : 2024-04-24 Nikita Arumalla, Zijing Yang, Sam Norton, Melissa Crooks, Ayesha Khan, Rebecca Fitzgerald, Rory Gilligan, Emily Lindberg, Toktan Tabibi, Yik L Man, Sujith Subesinghe, James B Galloway, Toby Garrood
Background/Aims Routine collection of electronic patient reported outcome measures (ePROMs) can facilitate dynamic disease activity monitoring in patients with inflammatory arthritis (IA). In a real-world cohort of patients with IA, we describe patient characteristics associated with ever engaging with ePROMs, evaluate whether there are distinct groups of patients with similar engagement trajectories
-
E026 Severe odynophagia due to cricoarytenoid arthritis in a patient with rheumatoid arthritis and systemic lupus erythematosus Rheumatology (IF 5.5) Pub Date : 2024-04-24 Joe S Berry, John Robinson, Wan-Fai Ng
Background/Aims A 65-year-old man with a 20-year history of rheumatoid arthritis (RA) presented with dysphagia, odynophagia, polyarthralgia and significant weight loss. Methods - Results In addition to raised markers of inflammation, he was anti-nuclear antibody, anti-dsDNA antibody, anti-chromatin antibody and rheumatoid factor positive. He was initiated on 20mg once daily prednisolone but reported
-
OA30 Primary osteoarthritis chondrocyte map of chromatin conformation reveals novel effector genes Rheumatology (IF 5.5) Pub Date : 2024-04-24 Norbert Bittner, Chenfu Shi, Danyun Zhao, James Ding, Lorraine Southam, Diane Swift, Peter Kreitmaier, Mauro Tutino, Jenny Hankinson, Mark Wilkinson, Gisela Orozco, Eleftheria Zeggini
Background/Aims Osteoarthritis is a complex disease with a huge public health burden. Genome-wide association studies (GWAS) have identified hundreds of osteoarthritis-associated sequence variants, but the effector genes underpinning these signals remain largely elusive. Understanding chromosome organisation in 3D space is essential for identifying long-range contacts between distant genomic features
-
E054 Rituximab dose minimisation in rheumatoid arthritis, a retrospective outcome analysis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Stephanie Butler, Helen Smith
Background/Aims Rituximab was originally developed as a non-Hodgkin lymphoma treatment and rheumatology adopted the same dosing for rheumatoid arthritis(RA); two 1000mg doses two weeks apart for each maintenance cycle. UHSussex utilises self-referral for maintenance rituximab dosing once disease control lessens. Evidence demonstrates patients treated with lower dose rituximab still enjoy good disease
-
P172 An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis treated with ixekizumab from 26 clinical studies Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sergio Schwartzman, Luis Puig, Arnon D Cohen, Saakshi Khattri, Christian Jossart, Carlos Diaz, Alyssa Garrelts, Danting Zhu, Nadezhda Eberhart, Areti Eleftheriadi, Nithi Tangsirisap, Christopher Schuster, Alice B Gottlieb, Mohamed Sheesh
Background/Aims Interleukin (IL)-17 plays a role in host defense against common extracellular pathogens, including fungi. Treatment with IL-17 inhibitors has been associated with fungal infections. Ixekizumab (IXE) is an anti-IL-17A monoclonal antibody approved for the treatment of psoriasis (PsO) in adults and children, psoriatic arthritis (PsA) in adults, and axial spondyloarthritis (axSpA) in adults
-
P007 Successful use of patient initiated follow-up in a tertiary paediatric rheumatology service Rheumatology (IF 5.5) Pub Date : 2024-04-24 William Calvert, Jean Spinty, Liza J McCann, Gavin Cleary
Background/Aims Patient initiated follow-up (PIFU) is a national strategy enabling patients or carers to initiate contact with a service rather than a traditional model of routine scheduled appointments. PIFU enables patient empowerment and elective recovery after the Covid-19 pandemic. NHSE identified Paediatrics as appropriate for PIFU, but specific measures are needed to ensure safeguarding of paediatric
-
E023 Intimomedial mucoid degeneration. A rare vascular disease mimicking giant cell arteritis presentation Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sarah Black, Maria Wray, Helen Stewart, Ellen Durkan, Viktor Serafimov, Philip Davey, Lisa Smith
Background/Aims The accuracy of giant cell arteritis (GCA) diagnosis has greatly improved in recent years with increasing use of fast track clinics and vascular ultrasound. The “halo” sign is recognised as confirmation of a positive test and is considered virtually pathognomonic of GCA in the setting of a correlating clinical presentation. There are caveats to this and “false halos” have been reported
-
E049 Including psychosocial approaches in paediatric and adolescent rheumatology: a service evaluation of an online art therapy group intervention for children, young people, and families Rheumatology (IF 5.5) Pub Date : 2024-04-24 Simon S Hackett, Sharmila Jandial, Lucy Craig, Patricia Watts
Background/Aims Children and young people with long-term physical conditions may develop mental health problems that have an impact upon their daily lives and families. Rates of anxiety and depression in children with juvenile idiopathic arthritis are higher than in peers without this diagnosis. The impact of long-term conditions on children and young people’s mental health and the pressure it puts
-
P183 Cognitive function in polymyalgia rheumatica Rheumatology (IF 5.5) Pub Date : 2024-04-24 Patricia Harkins, Sharon Cowley, Robert Harrington, David Kane, Richard Conway
Background/Aims Over the past decade our understanding of the prevalence, and indeed impact, of cognitive impairment in rheumatic diseases has increased. An aging population coupled with systemic inflammation have been postulated as key drivers of increased cognitive decline in these conditions. Intact cognitive function is imperative not only for quality of life and maintenance of one’s functional
-
E052 Characterising the factors associated with response to pain management in patients with the Stickler syndrome Rheumatology (IF 5.5) Pub Date : 2024-04-24 Rohan Mudkavi, Nicholas Shenker
Background/Aims The Stickler syndrome is associated with functional changes in one of the COL2 (type 1, common), COL11 (type 2, uncommon) or COL9 (very rare) genes and causes early onset osteoarthritis. Previous studies have looked at the factors associated with response to pain management interventions in osteoarthritis, but none have done so in a Stickler syndrome cohort. We aimed to identify the
-
P091 Is my arthritis part of who I am or something I have? Age of onset makes a difference Rheumatology (IF 5.5) Pub Date : 2024-04-24 Richard P Beesley, Rebecca M Beesley, Kate Middleton, Andrea McBride
Background/Aims Patients with rheumatic and musculoskeletal conditions experience a wide range of emotions, and reflect differently upon their diagnosis. This collaborative study between three patient organisations explored how a diagnosis of a rheumatic condition affected a patient’s identity with the disease. Methods Adults in the UK aged 18+ who had any diagnosis of a musculoskeletal or rheumatic
-
P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Dennis McGonagle, Arthur Kavanaugh, Iain McInnes, Lars-Erik Kristensen, Joseph Merola, Bruce Strober, Rebecca Bolce, Jeffrey R Lisse, Jennifer Pustizzi, Christophe Sapin, Christopher Ritchlin
Background/Aims Nail psoriasis (PsO) is a strong predictor for the development of psoriatic arthritis (PsA) and has been reported in 63-83% of patients with PsA. Psoriatic nails are linked to arthritis in the adjacent distal interphalangeal joint (DIP) of fingers or interphalangeal joint of thumbs, and both can lead to severe functional impairment. In the SPIRIT-H2H study of adults with PsA, 354 of
-
OA12 Patient reported pregnancy outcomes and experiences in women with axial spondyloarthritis: preliminary results from a UK patient survey Rheumatology (IF 5.5) Pub Date : 2024-04-24 Amanda Mootoo, Maria Mouyis, Bayram Farisogullari, Pedro M Machado, Dale Webb, Jill Hamilton, Zoë Clark, Helena Marzo-Ortega
Background/Aims Axial spondyloarthritis (axSpA) affects women of childbearing age and is associated with increased prevalence of pregnancy complications. There are limited UK data published on women with axSpA and pregnancy. We aimed to analyse the pregnancy outcomes and perspectives from women in the UK with axSpA who have been pregnant, with a particular focus on their access to support, flares,
-
OA29 Epigenetic regulation of IL-4 promoter targeting p300 attenuating intervertebral disc degeneration and pain by inhibiting IL-1β Rheumatology (IF 5.5) Pub Date : 2024-04-24 Haowen Cui, Zhaomin Zheng
Background/Aims Low back pain (LBP) is a prevalent condition primarily caused by intervertebral disc degeneration (IVDD), which imposes a substantial social and medical burden. Effective targeted treatments to prevent the progression of IVDD and alleviate LBP are still lacking. p300, a critical member of the histone acetyltransferase (HAT) family, is involved in the regulation of inflammation. This
-
E008 Review of rheumatology care for women of childbearing age Rheumatology (IF 5.5) Pub Date : 2024-04-24 Marwa Mohareb, Sumaya Ahmed, Anurag Bharadwaj, Anupama Nandagudi
Background/Aims Autoimmune rheumatic diseases are frequently diagnosed in women of childbearing age. Managing these conditions during pregnancy is complex because commonly used disease-modifying antirheumatic drugs (DMARDs) can pose risks. Specialized care for this patient group is crucial, necessitating adherence to established rheumatology practice standards and British Society for Rheumatology (BSR)
-
P002 A comparison between radiologically reported osteopenia and the FRAX score as an indication for bone densitometry Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sourabh Srinivas, Katharine Hood, Hem Sapkota
Background/Aims Osteopenia is defined as a bone mineral density score between -1 and -2.5 standard deviations compared to a young adult reference mean (T-score) based on dual energy x-ray absorptiometry (DXA). Radiologists continue to use the term in a generic and qualitative manner to mean decreased bone mineral density, but they cannot distinguish between osteopenia and osteoporosis which means patients
-
P175 The Psoriatic Arthritis Impact of Disease 12-item questionnaire can replace other patient-reported outcome measures to facilitate disease monitoring in clinical practice Rheumatology (IF 5.5) Pub Date : 2024-04-24 Ryan M Hum, Khaled Hasanein, Leow T Hao, Jacob C Williams, Annie Cheung, Aditya Adhikarla, Annabel Choyce, Alice Newton, Caroline Clegg, Anne Barton, Pauline Ho
Background/Aims The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) was developed and validated to improve assessment of disease activity from the patient’s perspective. Several patient-reported outcome measures (PROMs) are relevant to PsA but completing several questionnaires at each clinic visit creates a time and administrative burden for patients and clinicians. Furthermore
-
P139 Self-assessment of scleroderma skin: validation of the PASTUL questionnaire Rheumatology (IF 5.5) Pub Date : 2024-04-24 Julia Spierings, Voon H Ong, Paco M J Welsing, Michael Hughes, John D Pauling, Francesco Del Galdo, Ariane L Herrick, Christopher P Denton
Background/Aims The PASTUL (Patient self-Assessment of Skin Thickness in Upper Limb) questionnaire was developed during the COVID pandemic to allow self-assessment of skin remotely in systemic sclerosis (SSc). The aim of this study was to validate PASTUL, evaluate responsiveness and assess impact of skin on quality of life. Methods SSc patients were included in four centres. The PASTUL questionnaire
-
P086 Trends in the Incidence and Management of Gout in England: A Nationwide Study using the OpenSAFELY Platform Rheumatology (IF 5.5) Pub Date : 2024-04-24 Mark D Russell, Jon Massey, Edward Roddy, Brian MacKenna, Seb Bacon, Ben Goldacre, Colm D Andrews, George Hickman, Amir Mehrkar, Arti Mahto, Andrew I Rutherford, Samir Patel, Maryam A Adas, Edward Alveyn, Deepak Nagra, Katie Bechman, Jo M Ledingham, Joanna Hudson, Sam Norton, Andrew Cope, James Galloway
Background/Aims Gout is the most common inflammatory arthritis worldwide, yet one of the worst managed. Few population-level studies have evaluated how the COVID-19 pandemic impacted on incidence, prevalence, management and hospitalisations for people with gout. We investigated this in England using the OpenSAFELY platform. Methods With the approval of NHS England, we conducted a population-level cohort
-
P103 Centralised pain in early rheumatoid arthritis predicts worse bodily pain outcomes Rheumatology (IF 5.5) Pub Date : 2024-04-24 Eoin Kelleher, Amanda J Wall, Maria T Sanchez-Santos, Vishvarani Wanigasekera, Anushka Irani (nee Soni)
Background/Aims Features of centralised pain, encompassing widespread pain and non-pain features such as multisensory hypersensitivity, fatigue, and sleep disturbance are common in RA. We hypothesise that centralised pain in early RA affects response to standard first-line treatment. Methods Prospective cohort study of adults with a clinical diagnosis of RA recruited from the early inflammatory arthritis
-
E070 Sustained and consistent efficacy of bimekizumab in patients with active psoriatic arthritis regardless of prior TNF-inhibitor status: results from the phase 3 BE OPTIMAL and BE COMPLETE trials Rheumatology (IF 5.5) Pub Date : 2024-04-24 William R Tillett, Barbara Ink, Rajan Bajracharya, Vanessa Taieb, Poonam Sharma, Dennis McGonagle, Laura C Coates, Iain B McInnes
Background/Aims Bimekizumab (BKZ), a humanised monoclonal IgG1 antibody that inhibits IL-17A and IL-17F, has demonstrated rapid efficacy in joint and skin outcomes for patients with active psoriatic arthritis (PsA) who are bDMARD-naïve (BE OPTIMAL; NCT03895203) and TNFi-inadequate responders (TNFi-IR) (BE COMPLETE; NCT03896581). Here we report longer-term PsA response criteria (PsARC) response, along
-
E033 Beyond the surface: artful imitation of Hodgkin’s lymphoma as axial spondyloarthritis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Prabin Khatri, J N Durga Rao Yadavalli, Kumar Shivam, Rajiva Gupta
Background/Aims Rheumatic conditions may be associated with different neoplastic-diseases. Sacroiliitis is not defined as a paraneoplastic syndrome in the literature and considered as the direct involvement of the sacral/iliac bones or sacroiliac joints. There are only few reported cases of back pain and sacroiliac bones/joint involvement as an initial presentation of Hodgkin’s lymphoma. Methods An
-
P066 Predictive Modeling of Infection Risk in Lupus Nephritis using Multiple Machine Learning Algorithms Rheumatology (IF 5.5) Pub Date : 2024-04-24 Jiaqian Zhang, pengfei Cai, Jiu Liu, Qibing Xie
Background/Aims The incidence of infections is considerably higher among patients with lupus nephritis (LN), and these infections significantly contribute to mortality rates. This study analysed the characteristics of peripheral blood lymphocyte subsets in LN patients, aiming at using machine learning (ML) methods to explore the risk factors of infection and establish a most effective ML algorithm
-
P064 It’s a long time to wait: exploring the support needs of people with rheumatoid arthritis starting methotrexate Rheumatology (IF 5.5) Pub Date : 2024-04-24 Sarah J Logan, Samantha Hider, Julie Green, Sarah Ryan
Background/Aims Methotrexate (MTX) is recommended as initial Disease Modifying Anti-Rheumatic Drug (DMARD) therapy for people with Rheumatoid Arthritis (RA) but often takes several months to become effective. Little is known about the support needs of people with RA whilst MTX takes effect. Methods 76 adults with RA referred for MTX counselling attending two rheumatology units in the West Midlands
-
P014 Treatment response in psoriatic arthritis: a comparison between the disease activity scores psoriatic arthritis response criteria and disease activity score-28 Rheumatology (IF 5.5) Pub Date : 2024-04-24 Khadijah Patel, Nisha Nair, Meghna Jani, Hector Chinoy, James Bluett, Anne Barton, Philippa Curry
Background/Aims Despite NICE guidelines recommending the use of the PsA response criteria (PsARC), to assess response to biologic therapies in patients with psoriatic arthritis (PsA), some clinicians use the Disease Activity Score (DAS-28) criteria, developed for rheumatoid arthritis. However, whether the two scores are interchangeable and/or capture similar information has not yet been explored. Here
-
P081 Out-patient management of gout in secondary care: Results from the North West regional audit Rheumatology (IF 5.5) Pub Date : 2024-04-24 Laura Gould, Anneliese Richards, Leanne Gray, Mirza Badarulla, Louise Mercer, Rashid Farid, Rebecca Heaton, Mariam Al-Attar, Megan Whitehead, Sanjeet Kamath, Lee-Suan Teh, Ayomikun Odekunle, Charlotte A Sharp, Abdulrahman Babiker, Stephen Hopping, Alexander Oldroyd, Karina Lazarewicz, Christopher Saleh, Sarah Horton, Dipak Roy, Ayo Opeseyitan, Dhivya Das, Sneha Varughese, Daniel Yidana, Surabhi Wig
Background/Aims Recommendations for gout management have significantly evolved as outlined by the latest National Institute for Health and Care Excellence (NICE), European League Against Rheumatism (EULAR), British Society for Rheumatology (BSR) and the Medicines and Healthcare products Regulatory Agency (MHRA) guidelines, with increased emphasis being placed on optimising cardiovascular risk. This
-
P102 Should Fibromyalgia be Diagnosed in Primary or Secondary Care? Rheumatology (IF 5.5) Pub Date : 2024-04-24 Mark P Sykes
Background/Aims Both the Rheumatology Getting It Right First Time (GIRFT) report, published in February 2021, and the British Society for Rheumatology (BSR) referral guidelines from October 2021 recommend not referring patients with suspected Fibromyalgia to Rheumatology services. In contrast the Royal College of Physicians (RCP) guidelines on Fibromyalgia from 2022 recommend that for unequivocal cases
-
P108 Filgotinib for Rheumatoid Arthritis: an observational cohort to assess clinical effectiveness in a single centre Rheumatology (IF 5.5) Pub Date : 2024-04-24 Christopher D Box, Susan Ramsay, Neil D McKay
Background/Aims Filgotinib, a Janus-kinase (JAK) 1 preferential inhibitor, was approved for use in the UK in moderate or severe rheumatoid arthritis (RA) in 2021, as monotherapy or in combination with Methotrexate. Evidence of real-world effectiveness is currently limited. Methods Patients prescribed Filgotinib between December 2021 and August 2022 in NHS Lothian were identified from pharmacy registration
-
P021 Uptake, safety, and effectiveness of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide study using data from the Clinical Practice Research Datalink Rheumatology (IF 5.5) Pub Date : 2024-04-24 Georgina Nakafero, Matthew J Grainge, Christian D Mallen, Tim Card, Jonathan S Nguyen Van-Tam, Abhishek Abhishek
Background/Aims The safety and effectiveness of pneumococcal vaccine in people with immune mediated inflammatory diseases (IMIDs) is not known, which may contribute to suboptimal uptake. We investigated UK wide pneumococcal vaccine uptake in adults with IMIDs, the association between pneumococcal vaccination and disease flares, and the effectiveness of pneumococcal vaccine in preventing pneumonia in
-
P026 Neurofascin antibodies complicating a case of severe systemic lupus erythematosus Rheumatology (IF 5.5) Pub Date : 2024-04-24 Philip Yee, Maria Mouyis
Background/Aims Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease that results in increased disease activity and damage compared to adult-onset SLE. There is increased medication burden, severe organ manifestations and higher incidence of renal, cardiovascular and neuropsychiatric (NP) involvement. Anti-nervous system (NS) antibodies are seen across immune mediated diseases
-
P030 Multiple autoantibody formation post COVID-19 infection Rheumatology (IF 5.5) Pub Date : 2024-04-24 Samsul Islam, Nicola Erb
Background/Aims COVID-19 has been linked to the formation of a number of autoantibodies. This case is an important reminder to clinicians interpreting autoantibody results in conjunction with clinical manifestations. A previously fit 51 year old gentleman, with no prior history of autoimmune disease required admission with respiratory symptoms in April 2020 consistent with COVID-19 infection. His acute
-
P017 Planned infliximab use during pregnancy for pakistani patients with immune-mediated inflammatory disease - case series of 12 patients Rheumatology (IF 5.5) Pub Date : 2024-04-24 Zaid Tayyab, Mohammad Haroon
Background/Aims Immune-mediated inflammatory diseases (IMIDs) affect mostly young females during their reproductive age. Therefore, a better understanding is needed about the possible disease effects in pregnancy, as well as the risks of fetal exposure to the medications used. Studies have shown that anti-TNF are considered safe and do not increase the risk of adverse events during pregnancy. Nevertheless
-
P095 Association between autism and chronic musculoskeletal pain; a single tertiary adolescent rheumatology centre experience Rheumatology (IF 5.5) Pub Date : 2024-04-24 Ellie Williams, Sophia Mavrommatis, James Glanville, Maria Leandro, Debajit Sen, Corinne Fisher
Background/Aims Autism is a common neurodevelopmental disorder and can present with atypical sensorimotor function and altered pain response. Evidence suggests that patients with autism have a different processing mechanism which can alter pain perception. Pain evaluation and management is often insufficient in patients with autism. Chronic musculoskeletal pain in adolescents is common and is frequently
-
E063 Discussion of contraception and family planning in the lupus clinic Rheumatology (IF 5.5) Pub Date : 2024-04-24 Knievel Mashida, Rosalind Benson, Angela Redfern, Christine Burton, Zoe Mclaren
Background/Aims Females with a diagnosis of systemic lupus erythematosus (SLE) have a higher risk of adverse pregnancy outcomes. Many medications used to treat SLE are teratogenic. Contraception counselling and discussion around family planning are essential to reduce pregnancy risks. This service evaluation aimed to evaluate the appropriateness of contraceptive advice given to females of childbearing
-
P084 Gout symptom improvements and patient outcomes with SEL-212 in gout refractory to conventional therapy: DISSOLVE I & II phase 3, double-blind, placebo-controlled clinical trials Rheumatology (IF 5.5) Pub Date : 2024-04-24 Herbert S B Baraf, Puja Khanna, Anand Patel, Joanna Sobierska, Jacquie Christie, Wesley DeHaan, Rehan Azeem, Peter G Traber, Alan Kivitz
Background/Aims Serum uric acid (sUA) ≥6.8 mg/dL often leads to severe clinical manifestations in gout refractory to conventional therapy. Uricase-based therapies can be effective, although immunogenicity can reduce efficacy and increase infusion-reaction risk. SEL-212 is a novel, once-monthly treatment of sequential infusions of tolerogenic nanoparticles containing sirolimus (SEL-110) followed by
-
E032 Low dose methotextrate induced leukoencephalopathy: a case report Rheumatology (IF 5.5) Pub Date : 2024-04-24 Parveen Doddamani, Alison Kinder
Background/Aims Methotextrate is a widely used disease modifying anti-rheumatic drug (DMARD) used to treat connective tissue disorder and inflammatory arthritis. Methotextrate induced neurological toxicity includes vomiting, headaches, blurred vision, mood alteration, somolescence, brain fog, hyperosmia, leukoencephalopathy and pseudo-stroke like syndrome. Here we report a case of methotextrate induced
-
E003 A quality improvement project looking into retinopathy screening for patients taking hydroxychloroquine at the Princess of Wales Hospital Rheumatology (IF 5.5) Pub Date : 2024-04-24 Aqeel Maqsood Anjum, Saqib Safdar, Suzanne Duffill, Charlotte Jenkins, Shaun Smale, Usha Srinivasan
Background/Aims Hydroxychloroquine (HCQ) is widely used in various rheumatic and dermatological conditions and the risk of associated retinal toxicity is more common than previously considered; an overall prevalence of 7.5% in patients taking HCQ for greater than 5 years, rising to 20 to 50% after 20 years of treatment. The Royal College of Ophthalmologists (RCOphth) revised guidelines (2020) advise
-
P158 Cutaneous vasculitis in systemic lupus erythematosus: trends of incidence and risk factors Rheumatology (IF 5.5) Pub Date : 2024-04-24 Ahmed Saleh, Caroline Gordon, John Reynolds
Background/Aims Cutaneous vasculitis (CV) is the most common form of vasculitis observed in patients with SLE; however, the precise epidemiological trends and underlying risk factors remain uncertain. The aim of this study was to define the incidence, prevalence, and risk factors of CV in systemic lupus erythematosus (SLE) patients over a period of 20 years. Methods The Birmingham Lupus Cohort is a
-
P035 BSR Digital resources- Spotlights and Podcasts The Story So Far Rheumatology (IF 5.5) Pub Date : 2024-04-24 Rosalind Benson, Louise Coulson, William J Gregory, Jennifer Lemon, Yik L Man, Kate Maxey, David Pilbury, Marina Serrano, Chris Wincup, Pippa A Watson, Spencer Ellis, Edward Chibueze Mbanasor, Mariam Malik, Bhagya Lakshmana Murthy
Background/Aims The British Society for Rheumatology (BSR) has an eLearning site for members. Due to increasing demand for online learning triggered in part by the COVID pandemic, a decision was made to create a BSR digital learning board and produce a broader range of content. Methods The Digital Learning Board (DLB) was formed in February 2021 consisting of trainees, nurses, Consultant Rheumatologists
-
P109 Ocular manifestation of rheumatoid arthritis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Insaf Fenniche, Zohra Aydi, Mehdi Somai, Fatma Daoud, Besma Ben Dhaou, Samir Kochbati, Imene Rachdi, Fatma Boussema
Background/Aims Ocular manifestation associated with rheumatoid arthritis (RA) is common and should be systematically investigated by an ophthalmological examination. It may precede or complicate the disease. It manifests as a dry-eye syndrome in 38% to 45% of cases, scleritis in 0.2 to 6.3% of cases, episcleritis in 0.17 to 3.7% of cases, and peripheral ulcerative keratitis in 3% of cases. The aim
-
P039 A systematic review and meta analysis of anti rheumatic drugs and pneumococcal vaccine immunogenicity in inflammatory arthritis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Deepak Nagra, Katie Bechman, Maryam Adas, Zijing Yang, Edward Alveyn, Samir Patel, Mark Russell, Sam Norton, Chris Wincup, Christopher Baldwin, James Galloway
Background/Aims Pneumococcal pneumonia is an important cause of morbidity and mortality amongst patients with inflammatory arthritis. Vaccination is recommended by the National Institute of Clinical Excellence (NICE) but it remains unclear how vaccine efficacy is impacted by different immunosuppressive agents. Our objective was to compare the chance of a seroconversion following vaccination against
-
P031 An case of cryofibrinogen associated necrotising cutaneous vasculitis on background of aortitis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Antonios Psarras, Joel David, Raashid Luqmani, Shirish Dubey
Background/Aims Cryofibrinogen is an abnormal protein that forms precipitate in plasma but not in serum. Cryofibrinogenaemia can be detected in healthy individuals and patients with autoimmune diseases, cancer, and infections. Current data suggest that isolated cryofibrinogenaemia can be detected in up to 3% of healthy individuals and it is usually asymptomatic. However, cryofibrinogenaemia can be
-
P065 Patient-initiated follow up in rheumatoid arthritis: a systematic review and meta-analysis Rheumatology (IF 5.5) Pub Date : 2024-04-24 Edward Alveyn, Rory Crowder, Mark Perry, Sam Norton, James Galloway
Background/Aims Inflammatory arthritides including rheumatoid arthritis (RA) typically require lifelong outpatient care. Patient-initiated follow up (PIFU) has been employed to alleviate burdens on over-stretched rheumatology clinics, aiming to eliminate unnecessary clinic visits and reduce waiting times. There is a paucity of robust data to establish whether clinical outcomes differ under PIFU compared
-
P023 A case of ANCA-associated vasculitis with possible IgG4-related disease Rheumatology (IF 5.5) Pub Date : 2024-04-24 Hala Eltahir, Mark Lloyd
Background/Aims IgG4-related disease (IgG4-RD) and granulomatous polyangiitis (GPA) have apparent different pathology. There are infrequent reports of the two conditions occurring simultaneously. We add to the literature by describing a patient who appears to have both conditions. Methods A 65-year-old male presented with low back pain radiating to the perineum. His past history included T2DM, CABG